Comparative Pharmacology
Head-to-head clinical analysis: REVATIO versus STENDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVATIO versus STENDRA.
REVATIO vs STENDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REVATIO (sildenafil) is a phosphodiesterase type 5 (PDE5) inhibitor. By inhibiting PDE5, it increases cyclic guanosine monophosphate (cGMP) levels in pulmonary vascular smooth muscle, leading to vasodilation and reduced pulmonary vascular resistance.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation in corpus cavernosum, leading to smooth muscle relaxation and increased penile blood flow.
20 mg orally three times daily, administered 4-6 hours apart.
50 mg orally once daily as needed, 1 hour before sexual activity. Maximum dose 100 mg. Maximum frequency once daily.
None Documented
None Documented
Terminal elimination half-life ~4 hours (range 3-5 hours) in steady state; similar in pulmonary arterial hypertension patients.
Terminal elimination half-life is approximately 4 hours in healthy subjects; may be prolonged in hepatic impairment (Child-Pugh B: up to 6 hours) or with concomitant CYP3A4 inhibitors.
Primarily hepatic metabolism (CYP3A4) to N-desmethyl sildenafil (active). Renal excretion accounts for ~80% as metabolites; ~13% fecal.
Fecal (approximately 63%) and renal (approximately 21%) as metabolites; less than 2% excreted unchanged in urine.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor